Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer
In this real-world study in which patients were often switched to EI dosing after initial SI therapy, safety and efficacy of EI dosing were maintained in patients with breast cancer. As more patients are treated with EI dosing, this data provides new evidence that switching to EI dosing is safe and effective, while improving medication burden for patients.
Authors
- Joanne E. Mortimer (ORCID: https://orcid.org/0000-0002-2935-1934)
- Heather L. McArthur (ORCID: https://orcid.org/0000-0002-0201-3871)
- Irene Kang (ORCID: https://orcid.org/0000-0002-9472-3853)
- Nora Ruel (ORCID: https://orcid.org/0000-0002-4591-3618)
- Austin Kordic
- Alexis LeVee (ORCID: https://orcid.org/0000-0001-9821-8144)
- Melissa G. Lechner (ORCID: https://orcid.org/0000-0002-4744-6566)
- Karen Tsai (ORCID: https://orcid.org/0000-0003-2977-5849)
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
- Southwestern Medical Center (US)
- City of Hope (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1093/oncolo/oyaf371
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health